Clinical Trials · NCT00103935
Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 45
- Start date
- Feb 2005
- Locations
- 7 sites, United States
- Primary endpoint
- Assess the safety, tolerability, and pharmacokinetics of exenatide long-acting release (LAR) administered weekly by subcutaneous (SC) injection in subjects with type 2 diabetes (T2DM)